Trial Profile
Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Brain cancer; Glioblastoma
- Focus Therapeutic Use
- 29 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2016 New trial record